Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
- PMID: 28573708
- PMCID: PMC5697639
- DOI: 10.1111/dom.13022
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
Abstract
The range of glycated haemoglobin (HbA1c) responses and characteristics associated with above-average response to exenatide twice daily and once weekly were examined. Data were pooled from 8 exenatide-twice-daily and 5 exenatide-once-weekly studies. A baseline HbA1c-corrected measure of change in HbA1c after 24 weeks identified high, average and low responses. Multiple linear regression and multivariate generalized estimating equation models identified factors associated with high response. Among 2355 participants (exenatide twice daily, n = 1414; exenatide once weekly, n = 941), baseline HbA1c correlated with change in HbA1c (P < .0001). Across baseline HbA1c levels, the 25th to 75th percentile of HbA1c change ranged from -0.3% to -3.2% with exenatide twice daily and from -0.5% to -3.6% with exenatide once weekly. Asian ethnicity and older age were significantly associated with high response to exenatide twice daily; no factors were significantly associated with response to exenatide once weekly. These data provide clinically useful information for estimating the likelihood that, depending on baseline HbA1c, an individual can achieve HbA1c goals. The association between Asian ethnicity, age and high response to exenatide twice daily may relate to the specific effects of exenatide twice daily on postprandial glucose.
Keywords: exenatide once weekly; exenatide twice daily; glucagon-like peptide-1 receptor agonist; predictors.
© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Conflict of interest statement
J. E. S. has received honoraria for advisory boards and lectures from AstraZeneca, BGP Products, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. B. G. has received honoraria for advisory boards and lectures from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. J. H. is a consultant for AstraZeneca. E. H. is an employee of AstraZeneca. G. S. has received honoraria for advisory boards and lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi, and Takeda.
Figures
Similar articles
-
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.Diabetes Obes Metab. 2018 Jan;20(1):165-172. doi: 10.1111/dom.13056. Epub 2017 Aug 22. Diabetes Obes Metab. 2018. PMID: 28685973 Free PMC article. Clinical Trial.
-
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.Diabetes Obes Metab. 2017 May;19(5):672-681. doi: 10.1111/dom.12872. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 28058769 Free PMC article. Clinical Trial.
-
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.Diabetes Obes Metab. 2018 Jul;20(7):1602-1614. doi: 10.1111/dom.13266. Epub 2018 Mar 25. Diabetes Obes Metab. 2018. PMID: 29473704 Free PMC article. Clinical Trial.
-
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].Med Clin (Barc). 2014 Sep;143 Suppl 2:23-7. doi: 10.1016/S0025-7753(14)70105-8. Epub 2014 Oct 15. Med Clin (Barc). 2014. PMID: 25437462 Review. Spanish.
-
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29. Diabetes Obes Metab. 2016. PMID: 26511102 Free PMC article. Review.
Cited by
-
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).Cardiovasc Diabetol. 2022 Jun 27;21(1):116. doi: 10.1186/s12933-022-01555-z. Cardiovasc Diabetol. 2022. PMID: 35761271 Free PMC article. Clinical Trial.
-
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. Commun Med (Lond). 2023. PMID: 37794166 Free PMC article.
-
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.medRxiv [Preprint]. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868. medRxiv. 2023. Update in: Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. PMID: 37131814 Free PMC article. Updated. Preprint.
References
-
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. - PubMed
-
- McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs. 2014;74:325–351. - PubMed
-
- Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open‐label, non‐inferiority study. Lancet. 2008;372:1240–1250. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical